Cargando…

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC). These combinations have resulted in increased progression-free survival (PFS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Wânia Cristina, de Araujo, Vânia Eloisa, Lima, Ellias Magalhães e Abreu, dos Santos, Jessica Barreto Ribeiro, Silva, Michael Ruberson Ribeiro da, Almeida, Paulo Henrique Ribeiro Fernandes, de Assis Acurcio, Francisco, Godman, Brian, Kurdi, Amanj, Cherchiglia, Mariângela Leal, Andrade, Eli Iola Gurgel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290722/ https://www.ncbi.nlm.nih.gov/pubmed/30499082 http://dx.doi.org/10.1007/s40259-018-0322-1

Ejemplares similares

Legal and health variations in drug litigation injunctions granted in Minas Gerais
por: Coelho, Tiago Lopes, et al.
Publicado: (2014)

Health self-assessment by hemodialysis patients in the Brazilian Unified Health System
por: Moreira, Tiago Ricardo, et al.
Publicado: (2016)

The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil
por: Maia Diniz, Isabela, et al.
Publicado: (2018)

Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil
por: Guerra, Augusto Afonso, et al.
Publicado: (2015)

Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019)

Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting
por: Simino, Giovana Paula Rezende, et al.
Publicado: (2020)

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
por: da Silva, Michael Ruberson Ribeiro, et al.
Publicado: (2022)

Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System
por: Braga, Sonia Faria Mendes, et al.
Publicado: (2017)

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
por: Faria, Ronaldo José, et al.
Publicado: (2022)

Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System
por: de Souza, Elisa Neide Barbosa, et al.
Publicado: (2022)

Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2016)

Building the National Database of Health Centred on the Individual: Administrative and Epidemiological Record Linkage - Brazil, 2000-2015
por: Guerra Junior, Augusto Afonso, et al.
Publicado: (2018)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System
por: Gomes, Rosângela Maria, et al.
Publicado: (2020)

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
por: TSUKIHARA, HIROSHI, et al.
Publicado: (2015)

Duration of temporary catheter use for hemodialysis: an observational, prospective evaluation of renal units in Brazil
por: Bonfante, Gisele MS, et al.
Publicado: (2011)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
por: Xu, Yifan, et al.
Publicado: (2018)

Use of medicinal plants during COVID-19 pandemic in Brazil
por: da Silva, Alciellen Mendes, et al.
Publicado: (2023)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
por: Taniguchi, Hiroya, et al.
Publicado: (2020)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines
por: Bazoni, Patrícia Silva, et al.
Publicado: (2023)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?
por: Kurdi, Amanj, et al.
Publicado: (2020)

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer
por: Yokokawa, Hideyuki, et al.
Publicado: (2020)

(Un)Equitable distribution of health resources and the judicialization of healthcare: 10 years of experience in Brazil
por: Lopes, Luciana de Melo Nunes, et al.
Publicado: (2019)

Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies
por: Nascimento, Guilherme Fagundes, et al.
Publicado: (2020)

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution
por: SONODA, HIROMICHI, et al.
Publicado: (2013)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Estimated indirect costs of haemodialysis versus peritoneal dialysis from a patients’ perspective at an Academic Hospital in Pretoria, South Africa
por: Moalosi, Kotulo, et al.
Publicado: (2023)

Dezesseis Anos de Transplante Cardíaco em Coorte Aberta no Brasil: Análise de Sobrevivência de Pacientes em Uso de Imunossupressores
por: Freitas, Natália Cristina Cardoso, et al.
Publicado: (2021)

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dhsrpn1opr60087k7opv1sed6s